



ADULT MEDICATION GUIDELINE

Agomelatine

Scope (Staff): All WNHS Staff

Scope (Area): Obstetrics and Gynaecology

This document should be read in conjunction with the [Disclaimer](#).

Quick Links

[Dose](#)

[Administration](#)

[Monitoring](#)

[Pregnancy and
Breastfeeding](#)

Restrictions

Non-Formulary - [IPA Required](#)

Medication Class

Antidepressants

Presentation

Tablet: 25mg

Storage

Store in a dry place, at room temperature, below 30°C

Dose

For sleep and mood improvement in selected MBU patients

Oral:

Initially 25mg at bedtime; increase to 50mg at bedtime after 2 weeks if necessary

Administration

Oral

May be taken with or without food

Monitoring

Check liver function tests at baseline and before a dose increase, then at 3,6,12 and 24 weeks after commencing treatment or after a dose increase.

Repeat tests within 48 hours if aminotransferases rise.

Stop treatment if aminotransferases increase to > 3 times ULN or there are other signs of hepatic injury.

Monitor patients frequently and carefully early in treatment as increased suicidal thoughts and behaviour can occur soon after starting antidepressants.

Pregnancy

1st Trimester: Consider alternative

2nd Trimester: Consider alternative

3rd Trimester: Consider alternative

For more information, please contact [KEMH Obstetric Medicines Information Service](#).

Breastfeeding

Consider alternative

For more information, please contact [KEMH Obstetric Medicines Information Service](#).

Related Policies, Procedures & Guidelines

NMHS Mental Health Area Wide Policy

[Medication: Prescribing Greater than the Maximum Dose](#)

WNHS Clinical Practice Guideline

[Women's and Perinatal Mental Health Referral and Management](#)

References

Australian Medicines Handbook. Agomelatine. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2022 [cited 2022 Apr 28]. Available from: <https://amhonline.amh.net.au/>

Therapeutic Guidelines. Psychotropic: Major Depression. In: eTG complete [Internet]. West Melbourne (Victoria): Therapeutic Guidelines; 2021 [cited 2022 Apr 28]. Available from: <https://tgldcdp-tg-org-au.kelibresources.health.wa.gov.au/etgcomplete>

MIMS Australia. Valdoxan tablets. In: MIMS Online [Internet]. St Leonards (New South Wales): MIMS Australia; 2022 [cited 2022 Apr 28]. Available from: <https://www-mimsonline-com-au.kelibresources.health.wa.gov.au/Search/Search.aspx>

The Royal Women's Hospital. Agomelatine. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2021 [cited 2022 Apr 28]. Available from: <https://thewomenspbmg.org.au/>

Keywords	Agomelatine, Valdoxan®, depression, sleep				
Document Owner:	Chief Pharmacist				
Author/ Reviewer	KEMH Pharmacy Department				
Version Info:	4.0				
Date First Issued:	Dec 2014	Last Reviewed:	28/04/2022	Review Date:	28/04/2025
Endorsed by:	Medicines and Therapeutics Committee			Date:	05/07/2022
NSQHS Standards Applicable:	<input checked="" type="checkbox"/>  Std 1: Clinical Governance <input type="checkbox"/>  Std 2: Partnering with Consumers <input type="checkbox"/>  Std 3: Preventing and Controlling Healthcare Associated Infection <input checked="" type="checkbox"/>  Std 4: Medication Safety		<input type="checkbox"/>  Std 5: Comprehensive Care <input type="checkbox"/>  Std 6: Communicating for Safety <input type="checkbox"/>  Std 7: Blood Management <input type="checkbox"/>  Std 8: Recognising and Responding to Acute Deterioration		
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from WNHS HealthPoint.					

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2022

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.